Needham & Company LLC reissued their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) in a report issued on Thursday,Benzinga reports. Needham & Company LLC currently has a $56.00 price target on the specialty pharmaceutical company’s stock, up from their prior price target of $54.00.
COLL has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Collegium Pharmaceutical in a research note on Friday. Truist Financial set a $58.00 price objective on Collegium Pharmaceutical in a research report on Tuesday, February 10th. Weiss Ratings cut Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. Wall Street Zen downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $53.40.
Read Our Latest Report on Collegium Pharmaceutical
Collegium Pharmaceutical Trading Down 2.2%
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, missing the consensus estimate of $2.20 by ($0.16). The company had revenue of $205.45 million during the quarter, compared to the consensus estimate of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. Collegium Pharmaceutical’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.77 EPS. Equities research analysts forecast that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.
Insider Buying and Selling at Collegium Pharmaceutical
In other news, EVP Scott Dreyer sold 49,976 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total value of $2,019,530.16. Following the completion of the sale, the executive vice president owned 71,770 shares of the company’s stock, valued at approximately $2,900,225.70. This represents a 41.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP David Dieter sold 13,976 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total value of $488,041.92. Following the transaction, the executive vice president owned 77,071 shares of the company’s stock, valued at $2,691,319.32. This trade represents a 15.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.51% of the stock is owned by company insiders.
Institutional Trading of Collegium Pharmaceutical
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rubric Capital Management LP raised its holdings in Collegium Pharmaceutical by 5.3% during the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock worth $93,374,000 after purchasing an additional 157,743 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Collegium Pharmaceutical by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after purchasing an additional 29,876 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Collegium Pharmaceutical by 1.1% during the fourth quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock worth $74,883,000 after buying an additional 18,160 shares during the period. Janus Henderson Group PLC increased its position in shares of Collegium Pharmaceutical by 59.1% during the fourth quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after buying an additional 538,337 shares during the period. Finally, Principal Financial Group Inc. raised its stake in Collegium Pharmaceutical by 0.3% during the fourth quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company’s stock worth $60,823,000 after buying an additional 3,891 shares during the last quarter.
More Collegium Pharmaceutical News
Here are the key news stories impacting Collegium Pharmaceutical this week:
- Positive Sentiment: Collegium agreed to acquire AZSTARYS from Corium, adding a differentiated ADHD medicine to its portfolio; company says the asset is expected to generate over $50M in pro‑forma net revenue in H2 2026, offers patent protection into 2037, and the deal is expected to be immediately accretive to adjusted EBITDA. Collegium to Acquire AZSTARYS from Corium Therapeutics (GlobeNewswire)
- Positive Sentiment: Sell‑side support strengthened: HC Wainwright reaffirmed a Buy with a $60 PT and Needham reaffirmed Buy with a $56 PT — both imply substantial upside vs. the recent share price, which can underpin investor confidence. Analyst Coverage (Benzinga)
- Neutral Sentiment: Conference call and management discussion transcripts are available for investors seeking details on deal economics and integration plans. Acquisition Discussion Transcript (Seeking Alpha)
- Neutral Sentiment: FDA news elsewhere in the pharma sector: PharmExec reports approval of Wegovy HD (Novo Nordisk) — relevant for sector context but not directly tied to Collegium’s ADHD/pain-focused franchise. FDA Approves Wegovy HD (PharmExec)
- Neutral Sentiment: Public press coverage shows deal price described with varying figures (reports cite up to $785M and also $650M headlines) — read releases for definitive terms. Collegium to buy AZSTARYS for up to $785M (MSN)
- Negative Sentiment: The acquisition costs and financing raise near‑term financial risk: the deal is being funded from cash on hand plus a previously announced $300M delayed‑draw term loan, which increases leverage for a company that already shows a relatively high debt/equity ratio; investors may worry about cash burn, integration execution and balance‑sheet pressure. Deal Coverage (FiercePharma)
- Negative Sentiment: Recent quarterly results (Feb. 26) showed a slight revenue and EPS miss vs. consensus, which combined with the large acquisition outlay can pressure near‑term sentiment as investors await proof the deal accelerates growth. Earnings Summary (Benzinga)
- Neutral Sentiment: Reported short‑interest data appears anomalous (shows zero shares), so it does not provide a meaningful read into market positioning at this time.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.
The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.
Recommended Stories
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
